Boehringer Ingelheim Venture Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 13
- Investments
- 83
- Portfolio
- 38
- Exits
- 15
Boehringer Ingelheim Venture Fund General Information
Description
Established in 2010, Boehringer Ingelheim Venture Fund is a venture capital arm of Boehringer Ingelheim headquartered in Ingelheim am Rhein, Germany. The firm prefers to invest in companies operating in the healthcare sector.
Contact Information
Year Founded
2010
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Corporate Venture Capital
Primary Office
- Binger Straße 173
- 55216 Ingelheim am Rhein
- Germany
+49 06132 00000000
Boehringer Ingelheim Venture Fund Investments (83)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Topas Therapeutics | 29-Jul-2021 | Later Stage VC | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 000000000 00000 00.0 |
| 0000000000 | 14-Jul-2021 | 00000 00000 | 000.00 | Other Healthcare Technology Systems | Clinical Trials - General | 000000 00000 |
| 000000 | 23-Jun-2021 | 00000 00000 | 000.00 | Outcome Management (Healthcare) | Generating Revenue/Not Profitable | 0000 00000 |
| 00000000 | 30-Apr-2021 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 00000 00000 00.0 |
| 00000 000000000000 | 20-Apr-2021 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | 00000 00000000000 00.0 |
| 0000.000 | 31-Mar-2021 | 00000 00000 | Managed Care | Stealth | ||
| 000000 00000000000 | 10-Mar-2021 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 0000 00000 00.0 |
| 0000000 00000000 | 10-Mar-2021 | 0000 00000 | 0000 | Pharmaceuticals | Startup | |
| Perfood | 30-Nov-2020 | Early Stage VC | 00.000 | Other Healthcare Technology Systems | Generating Revenue | 000000 00000 |
| ImCheck Therapeutics | 15-Sep-2020 | Later Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 000000 000000000 00.0 |
Boehringer Ingelheim Venture Fund Exits (15)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Abexxa Biologics | 21-Sep-2021 | Merger/Acquisition | |
| 0000 0000000000000 | 04-Jan-2021 | 000000000000000000 | 0000 |
| 000 000000000000 | 01-Dec-2020 | 000000000000000000 | 00.00 |
| 0000000 | 20-Apr-2020 | 000000000000000000 | |
| 0000 000000000000 | 15-Jul-2019 | 000000000000000000 | 00000 |
| 00000 000000000000 | 01-Jun-2019 | 000000000000000000 | 00000 |
| 0000000 000000 | 18-Apr-2019 | 000 | 0000 |
| 000 000000000000 | 29-Mar-2019 | 000000000000000000 | |
| ViraTherapeutics | 13-Sep-2018 | Merger/Acquisition | 00000 |
| STAT-Dx | 19-Apr-2018 | Merger/Acquisition | 00000 |
Boehringer Ingelheim Venture Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBoehringer Ingelheim Venture Fund Team (30)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Martin Heidecker Ph.D | Managing Director | 0 | 0 | 0 | Cambridge, MA |
| Weiyi Zhang Ph.D | Managing Director | 0 | 0 | 0 | Beijing, China |
| Frank Kalkbrenner Ph.D | Global Head, Director & Investment Manager | 00 | 0 | 00 | Ingelheim am Rhein, Germany |
| Viktor Dzimiera | Finance Director | Ingelheim am Rhein, Germany | |||
| Markus Barner | Executive | Ingelheim am Rhein, Germany |
Boehringer Ingelheim Venture Fund Co-Investors (152)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| High-Tech Gründerfonds | 6 | 0 | 0 |
|
|
| BioMedPartners | 0 | 0 | 0 |
|
|
| Life Sciences Partners | 0 | 0 |
|
|
|
| PMV | 0 | 0 |
|
|
|
| Pontifax Venture Capital | 0 | 0 |
|
|